Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05681624 · ClinicalTrials.gov registry record · NA
Maternal Oxygen Supplementation for Intrauterine Resuscitation
A NA study of Fetal Hypoxia and Fetal Distress, sponsored by Washington University School of Medicine.
- Recruiting
- Registry status
- NA
- Development phase
- 2,124
- Enrollment target
- 1
- Study location
NCT05681624: Recruiting NA study of Fetal Hypoxia and Fetal Distress, sponsored by Washington University School of Medicine.
NCT05681624 is a NA study of Fetal Hypoxia and Fetal Distress that is actively recruiting participants, run by Washington University School of Medicine. The registered enrollment target is 2,124 participants, above the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (51% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05681624, a NA study of Fetal Hypoxia and Fetal Distress, is actively recruiting participants, sponsored by Washington University School of Medicine.
- RECRUITING
- Registry status
- NA
- Development phase
- 2,124 participants
- Enrollment target
- 1
- Study location
Study Summary
More than 80% of the 3 million women who labor and deliver each year in the United States undergo continuous electronic fetal monitoring (EFM) during labor in order to fetal hypoxia and prevent the transition to acidemia, expedited operative delivery, and/or neonatal morbidity. Category II EFM is the most commonly observed group of fetal heart rate features in labor. One common response to Category II EFM is maternal oxygen (O2) supplementation. The theoretic rationale for O2 administration is that it increases O2 transfer to a hypoxic fetus. There are conflicting national guidelines regarding O2 administration - the American College of Obstetricians and Gynecologists suggest O2 is ineffective, whereas the Association of Women's Health, Obstetric, and Neonatal Nurses recommend continued use given lack of definitive data on safety and efficacy. A recent national survey of nearly 600 Labor \& Delivery providers in February 2022 revealed that 49% still use O2 . Thus, there remains equipoise on the topic and high-quality data on the safety of intrapartum O2 is needed. None of the trials to date have studied the effect of intrapartum O2 on important clinical measures of neonatal or maternal morbidity. This safety data is imperative because the field of obstetrics must hold supplemental O2 to the same rigorous standards applied to any drug used in pregnancy. Without data on these definitive outcomes, it will be challenging to implement evidence-based recommendations for supplemental O2 use on Labor \& Delivery. The investigators will conduct a large, multicenter, randomized noninferiority trial of O2 supplementation versus room air in patients with Category II EFM in labor.
Primary Outcome
One of the following diagnoses: Neonatal death, acidemia, meconium aspiration with pulmonary hypertension, hypoglycemia, hypoxic ischemic encephalopathy ,hypothermia treatment, seizure, respiratory distress
Conditions Studied
Interventions
- OTHER Maternal oxygen supplementation
- OTHER Room air
Study Locations (1)
Missouri
- Barnes Jewish Hospital - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,124 participants |
| Start Date | 2023-05-22 |
| Est. Completion | 2028-12-31 |
| Phase | NA |
What NCT05681624 shows while recruiting
NCT05681624 is an interventional study that assigns participants to a tested intervention. Its 2,124 participants enrollment target places it among the larger protocols in the corpus, above the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (51% higher).
The record links to 3 conditions, with Fetal Hypoxia appearing as the primary indexed condition, and to 2 interventions - of which Maternal oxygen supplementation is the first listed.
NCT05681624 reports a single indexed study location in Missouri.
Frequently Asked Questions
What is clinical trial NCT05681624 about?
NCT05681624 is a clinical study titled "Maternal Oxygen Supplementation for Intrauterine Resuscitation". More than 80% of the 3 million women who labor and deliver each year in the United States undergo continuous electronic fetal monitoring (EFM) during labor in order to fetal hypoxia and prevent the transition to acidemia, expedited operative delivery, and/or neonatal morbidity. Category II EFM is th...
What is the current status of trial NCT05681624?
This trial is currently recruiting. It is a NA study. The enrollment target is 2,124 participants. The study started on 2023-05-22. Estimated completion is 2028-12-31.
What conditions does trial NCT05681624 study?
This clinical trial studies the following conditions: Fetal Hypoxia, Fetal Distress, Labor and Delivery Complication.
What interventions are being tested in trial NCT05681624?
The interventions under investigation include: Maternal oxygen supplementation (OTHER), Room air (OTHER).
Who is sponsoring clinical trial NCT05681624?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05681624 being conducted?
This trial has 1 study location across Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Fetal Hypoxia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05681624's enrollment target sits among peer trials
2,124 49th of 2000 higher than 1,952 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05916430 · 2,120 participants
Screening for Autism in 9-Month-Olds by Measuring Social Visual Engagement
- NCT07431281 · 2,130 participants · Phase 3
Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2
- NCT05650658 · 2,136 participants · NA
Left vs Left Randomized Clinical Trial
- NCT03488693 · 2,140 participants · Phase 3
Regional Radiotherapy in Biomarker Low-Risk Node Positive and T3N0 Breast Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI